Tennessee Oncology is home to one of the leading clinical trial networks in the country. We offer a broad menu of trial opportunities in every phase of treatment. Use the search below to discover and learn more about our clinical trials:
(EXPANSION) A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally to Patients with Advanced or Metastatic Solid Tumors
Condition: Multiple Solid Tumors
TO Study: RM 721
Clinic:
Cleveland, Chattanooga Downtown, MedPark 2, Memorial
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
Condition: Multiple Solid Tumors
TO Study: MULTI 67
Clinic:
Cleveland, Chattanooga Downtown, MedPark 2, Memorial
Phase 2 Open-label Study to Evaluate Momelotinib in Combination with Luspatercept in Participants with Transfusion Dependent Primary or Secondary Myelofibrosis
Condition: Myelofibrosis
TO Study: MPN24004
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer, Cleveland, Chattanooga Downtown, MedPark 2, Memorial
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Condition: Myelofibrosis
TO Study: MPN24003
Clinic:
Cleveland, Chattanooga Downtown, MedPark 2, Memorial, Dalton, Ringgold, Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
TO Study: MM23002
Clinic:
Tennessee Oncology Center for Blood Cancer, Midtown Center for Blood Cancer
Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Condition: Multiple Myeloma
TO Study: MM 163
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer
Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CAMMOUFLAGE Trial)
Condition: Multiple Myeloma
TO Study: MM 161
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Condition: Multiple Myeloma
TO Study: MM 136
Clinic:
Lebanon, Murfreesboro, Shelbyville, Mt. Juliet, Midtown Center for Blood Cancer, Midtown, Centennial Medical Center, Gallatin, Tennessee Oncology Center for Blood Cancer
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Treatment as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
Condition: Large B-Cell Lymphoma
TO Study: LYM 206
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL [APOLLO])
Condition: Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Large B-Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
TO Study: LYM 211
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
A PHASE III, MULTICENTER, RANDOMIZED, OPEN‑LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) VERSUS POLA‑R‑CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE…
Condition: Large B-Cell Lymphoma
TO Study: LYM24006
Clinic:
Centennial Medical Center, Midtown Center for Blood Cancer, Midtown, Tennessee Oncology Center for Blood Cancer, Chattanooga Downtown, Med Park, Memorial
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64407564, a Humanized GPRC5D x CD3 DuoBody® Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma
TO Study: MM 96
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
TO Study: MM 159
Clinic:
Tennessee Oncology Center for Blood Cancer, Midtown Center for Blood Cancer
A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, unresectable, locally advanced or…
Condition: Non-small Cell Lung Cancer
TO Study: LUN24019
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Mt. Juliet, Cleveland, Chattanooga Downtown, Dalton, Med Park, Memorial
A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
Condition: Follicular Lymphoma
TO Study: LYM 202
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies.
Condition: Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Primary Central Nervous System Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
TO Study: LYM 184
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Condition: Follicular Lymphoma
TO Study: LYM 170
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer
A Phase III, Randomized, Double-Blind, Multicenter, Global Study of Rilvegostomig in Combination with Chemotherapy for First-line Treatment of Patients with Metastatic Non-squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TC ≥ 1%) (ARTEMIDE-Lung03)
Condition: Non-small Cell Lung Cancer
TO Study: LUN24029
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park, Memorial
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)- ARTEMIA…
Condition: Non-small Cell Lung Cancer
TO Study: LUN24016
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park, Memorial
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on…
Condition: Non-small Cell Lung Cancer
TO Study: LUN24015
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Mt. Juliet
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer (GALAXIES LUNG-201)
Condition: Non-small Cell Lung Cancer
TO Study: LUN23023
Clinic:
Cleveland, Chattanooga Downtown, MedPark 2, Memorial
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
TO Study: LUN23013
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills
A Dose-escalation, Dose-finding, and Expansion Study of XL495 as a Single Agent and in Combination Therapy in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination with Anti-PD-1 in Advanced Solid Tumors
First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies
A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy
Condition: Urothelial Cancer
TO Study: GU 220
Clinic:
Cleveland, Chattanooga Downtown, MedPark 2, Memorial
A Phase I/II Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma or Multiple Myeloma
Condition: Multiple Myeloma
TO Study: HR 68
Clinic:
Tennessee Oncology Center for Blood Cancer, Midtown Center for Blood Cancer
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)
Condition: Head and Neck Squamous Cell Carcinoma
TO Study: HN23002
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park, Memorial, Ringgold
A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared with Investigator’s Choice Monotherapy Treatment in Previously Treated Patients with Incurable, Metastatic/recurrent Head and Neck Squamous Cell Carcinoma
Condition: Head and Neck Squamous Cell Carcinoma
TO Study: HN23003
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park, Memorial
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer: Triple Negative
TO Study: BRE 360
Clinic:
Cleveland, Chattanooga Downtown, MedPark 2, Memorial
Phase II, Open-Label, Prospective Single-Arm, Multi-Center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKI for 1L CLL Can Achieve Deep Durable Remissions (BY uMRD 10^-4) to Allow Off-Treatment Period​
Condition: Chronic Lymphocytic Leukemia
TO Study: CLL24004
Clinic:
Centennial Medical Center, Lebanon, Skyline, Midtown Center for Blood Cancer, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Tennessee Oncology Center for Blood Cancer, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park, Memorial, Ringgold
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer…
Condition: Breast Cancer: HR+/HER2-
TO Study: BRE24011
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive…
Condition: Breast Cancer: Triple Negative
TO Study: BRE23006
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park, Memorial, Ringgold
Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan(Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment…
Condition: Breast Cancer: Triple Negative
TO Study: BRE23005
Clinic:
Cleveland, Chattanooga Downtown, MedPark 2, Memorial, Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Murfreesboro, West, Shelbyville, Skyline, Smyrna, Southern Hills, Mt. Juliet
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast…
Condition: Breast Cancer: Triple Negative
TO Study: BRE 409
Clinic:
Cleveland, Chattanooga Downtown, MedPark 2, Memorial
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
Condition: Breast Cancer: HR+/HER2-
TO Study: BRE 405
Clinic:
Cleveland, Chattanooga Downtown, MedPark 2, Memorial
